Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H21NO2S.C4H4O4 |
| Molecular Weight | 407.481 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.OC1CN(CCCOCCC2=CC=C3SC=CC3=C2)C1
InChI
InChIKey=RLUCYBFCLXANSO-BTJKTKAUSA-N
InChI=1S/C16H21NO2S.C4H4O4/c18-15-11-17(12-15)6-1-7-19-8-4-13-2-3-16-14(10-13)5-9-20-16;5-3(6)1-2-4(7)8/h2-3,5,9-10,15,18H,1,4,6-8,11-12H2;1-2H,(H,5,6)(H,7,8)/b;2-1-
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000036826
Created by
admin on Sat Dec 16 09:16:51 UTC 2023 , Edited by admin on Sat Dec 16 09:16:51 UTC 2023
|
PRIMARY | |||
|
T-817 MALEATE
Created by
admin on Sat Dec 16 09:16:51 UTC 2023 , Edited by admin on Sat Dec 16 09:16:51 UTC 2023
|
PRIMARY | The primary objective of the study is to evaluate the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment. The secondary objectives of the study are to evaluate the safety of T-817MA and the activities of daily living (assessed with the ADCS-ADL) of AD patients taking T-817MA, and to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the ADCS-CGIC. | ||
|
0LB9F7I5P3
Created by
admin on Sat Dec 16 09:16:51 UTC 2023 , Edited by admin on Sat Dec 16 09:16:51 UTC 2023
|
PRIMARY | |||
|
519187-97-4
Created by
admin on Sat Dec 16 09:16:51 UTC 2023 , Edited by admin on Sat Dec 16 09:16:51 UTC 2023
|
PRIMARY | |||
|
DBSALT002609
Created by
admin on Sat Dec 16 09:16:51 UTC 2023 , Edited by admin on Sat Dec 16 09:16:51 UTC 2023
|
PRIMARY | |||
|
11338749
Created by
admin on Sat Dec 16 09:16:51 UTC 2023 , Edited by admin on Sat Dec 16 09:16:51 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
